TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00600106
Drug: 1/10 NA/EE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
Study: NCT00324467
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication for R-ICE Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
Study: NCT00600106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg placebo
Study: NCT00455507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo tablets orally once daily for 12 weeks
Study: NCT01701115
Drug: Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01701115
Drug: Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04606576
Drug: ORMD-0801 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Insulin once per day
Study: NCT01413360
Drug: High dose vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
Study: NCT01334723
Drug: Adherent with 5-alpha-reductase inhibitor (5ARI) therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
Study: NCT01334723
Drug: Non-adherent to 5ARI therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
Study: NCT03263208
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days(Day-5 to day-4).
Study: NCT04615611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of placebo
Study: NCT02912026
Drug: IV F901318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolic profile AUC 0 to infinity
Study: NCT02912026
Drug: Oral F901318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolic profile AUC 0 to infinity
Study: NCT01226381
Drug: Von Frey electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: This protocol is based on a study of the interaction setron / paracetamol at 4 different levels of plasma concentrations, by repeating the tests at set intervals, while concentrations of setrons down gradually (half-life of 8 to 10 am ) after a single administration. In addition, the interindividual variability of the effects of paracetamol will be studied, and linking with certain genetic polymorphisms reported by the subjects tested
Study: NCT00003679
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003679
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01524861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a placebo tablet bis in die for 12 months
Study: NCT03636906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose or 2 doses of Placebo administered intramuscularly at Day 31, or at Day 1 and Day 31, or at Day 1 and Day 61, or at Day 31 and Day 121, depending on the vaccination schedule.
Study: NCT01701362
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
Study: NCT03006614
Drug: CAP
Normalized name: CAP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03006614
Drug: H
Normalized name: Hb
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02243319
Drug: HGP1201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02243319
Drug: HGP0904
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01765036
Drug: SonoVue®
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
Study: NCT04329728
Drug: AVM0703
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion over \~1 hours
Study: NCT02497365
Drug: Tobramycin and Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fortified Tobramycin and Cefazolin eye drops
Study: NCT01026090
Drug: Placebo (for dronedarone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)
Study: NCT03147378
Drug: ModraDoc006/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
Study: NCT02346227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.~It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix.
Study: NCT01769664
Drug: Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
Study: NCT01769664
Drug: Duac® Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)
Study: NCT01769664
Drug: Placebo Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
Study: NCT02882438
Drug: infected group
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo Biloba in different dosage forms
Study: NCT02882438
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo without Ginkgo Biloba
Study: NCT01813201
Drug: Saline isotonic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
Study: NCT01602601
Drug: GSK2788723
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
Study: NCT02584452
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraoperative opioid should be limited to no more than 150mcg of fentanyl.
Study: NCT01107392
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
Study: NCT00654225
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02689206
Drug: GSK1278863
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
Study: NCT02689206
Drug: GSK1278863 matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
Study: NCT04528550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Included patients will receive the same amount of saline through lumbar injection.
Study: NCT00000401
Drug: Oral bovine type II collagen
Normalized name: bovine type II collagen (tracheal cartilage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug can be interrupted or stopped for suspected adverse events.
Study: NCT01013324
Drug: XL147 (SAR245408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosed as capsules taken orally daily
Study: NCT01415297
Drug: NKP-1339
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
Study: NCT00414323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01232127
Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 10 days
Study: NCT01232127
Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 7 days
Study: NCT03162796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo as SC injection.
Study: NCT02720523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; Oral
Study: NCT01632592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo given by injection 2mg subcutaneously daily
Study: NCT00333411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01642056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03522935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous.
Study: NCT03734926
Drug: ZSP1241
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1241 tablets for oral administration.
Study: NCT00182078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.
Study: NCT00532311
Drug: Stable statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
Study: NCT03180333
Drug: PNA
Normalized name: DPNase
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03180333
Drug: PNA placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01875393
Drug: TOOKAD® Soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
Study: NCT04393597
Drug: DWJ1458 (fed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take single dose of DWJ1458 after high-fat diet
Study: NCT02270632
Drug: F8IL10
Approvals — FDA: no, EMA: no, PMDA: no
Description: F8IL10 will be administered once a week for 8 weeks (or until withdrawn from the study).
Study: NCT03786926
Drug: HMPL-689
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-689 is a PI3Kδ inhibitor
Study: NCT03376139
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
Study: NCT00143624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See detailed description.
Study: NCT03789123
Drug: Estradiol valerate/dienogest
Normalized name: Estradiol Valerate and Estradiol Valerate/Dienogest KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.
Study: NCT03001193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00631813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: bid
Study: NCT03114111
Drug: aminolevulinic acid (ALA)
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03114111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01279291
Drug: pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
Study: NCT00375505
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00375505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01393795
Drug: Tegaderm
Normalized name: Tegaderm 4x4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active drug
Study: NCT04061824
Drug: Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination))
Approvals — FDA: no, EMA: no, PMDA: no
Description: In intervention group, patients had a pill of fixed-dose combination of Olmesartan medoxomil and Rosuvastatin, rather taking separated two pills.
Study: NCT04061824
Drug: Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In control group, patients had two separated pills for hypertension and dyslipidemia. One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin, Pravastatin, Fluvastatin and Atorvastatin/Ezetimibe).
Study: NCT02473094
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825mg/m2 bid, D1-D5 q7d
Study: NCT02473094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo up to 2500mg/d
Study: NCT02069821
Drug: combination administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)
Study: NCT01185951
Drug: Topical NO
Normalized name: thickening agent, topical no.1 TOPICAL LIQUID (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerine (Nitrolingualspray(R)) 2x2 hubs per day over 6 months daily on the painful tendon
Study: NCT00500461
Drug: GSK233705
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.
Study: NCT00460460
Drug: AZD4877
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03645278
Drug: SHR0532
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending dose oral adminstration
Study: NCT03645278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending dose oral administration
Study: NCT00803595
Drug: CS-8958
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
Study: NCT00803595
Drug: CS-8958
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
Study: NCT04118075
Drug: PT-CY-FK +/-ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
Study: NCT01163305
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
Study: NCT04304053
Drug: Treatment and prophylaxis
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7~Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7.
Study: NCT00792740
Drug: ITF2357
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF2357 was administered as hard gelatin capsules for oral administration at the dose strength of 50 mg. Capsules were administered as follow: one capsule in the morning and one in the evening.
Study: NCT02798744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for the duration of the study (24 weeks)
Study: NCT00055926
Drug: CP-724,714
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04124094
Drug: Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
Study: NCT04124094
Drug: Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations in one study period
Study: NCT01915537
Drug: Classic DMARDs treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.~Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time.
Study: NCT04590937
Drug: CRESTOR®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT02259361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
Study: NCT03323346
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper.
Study: NCT01272830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules taken twice daily with meals
Study: NCT01272830
Drug: Apatone®B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules taken twice daily with meals
Study: NCT04590937
Drug: Lenoxin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04590937
Drug: MetfoLiquid GeriaSan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT00777595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled solution, single dose of placebo
Study: NCT04590937
Drug: Lasix®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT02216916
Drug: HM781-36B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01530503
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months
Study: NCT04054921
Drug: PTG-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTG-300 is a hepcidin Mimetic
Study: NCT03375645
Drug: Any oral opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency department patients who receive a prescription for an oral opioid
Study: NCT00625391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg medicinal starch pills daily
Study: NCT04167007
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin at 85 mg/m² given as a 2 hours IV infusion on days 1 and 15; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) in 250 ml glucose 5% solution given as a 2 hours IV infusion on days 1 and 15; and 5-FU 2400 mg/m² administered as continuous 46-hour IV infusion on days 1-3 and 15-17, every 28 days.
Study: NCT01958775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00625391
Drug: Green Tea Polyphenols (GTP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg green tea polyphenols daily
Study: NCT00625391
Drug: Placebo+Tai Chi (TC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
Study: NCT01405963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in a 1-hour intravenous infusion
Study: NCT00891202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
Study: NCT01186887
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn